论文部分内容阅读
Peptide 6A(P6A)是一种纤维蛋白(元)降解产物,分子组成为Ala-Arg-Pro-Ala-Lys。现用固相法合成,HPLC纯化,经FABMS确认氨基酸序列,其纯度在98％以上。 用10~(-4)mol/L的P6A灌流离体大鼠心脏明显增加冠脉灌流量(CPF),且呈剂量依赖关系,在10~(-4)mol/L时CPF增加70.9±7.0％,停药10min后CPF仍高于对照水平。P6A灌流还轻度而短暂地增加心脏LVESP和LVdp/dt_(max),但对心率和LVEDP无明显影响。应用前列环素(PGI_2)灌流离体心脏,亦有类似的心脏效应。预先应用消炎痛(环氧化酶抑制剂)阻断PG合成,则明显抑制了P6A增加CPF的作用(抑制了75％)。用放射免
Peptide 6A (P6A) is a fibrin (meta) degradation product with the molecular composition of Ala-Arg-Pro-Ala-Lys. Now solid phase synthesis, HPLC purification, confirmed by FABMS amino acid sequence, the purity of more than 98%. Coronary perfusion (CPF) was significantly increased in isolated perfused rat hearts exposed to 10-4 mol / L P6A in a dose-dependent manner. CPF increased by 70.9 ± 7.0 at 10 -4 mol / L %, CPF is still higher than the control after stopping 10min. P6A perfusion also slightly and transiently increased LVESP and LVdp / dtmax, but had no significant effect on heart rate and LVEDP. Application of prostacyclin (PGI_2) perfused isolated heart, also have similar heart effect. Pretreatment of PG synthesis with indomethacin (cyclooxygenase inhibitor) significantly inhibited the effect of P6A in increasing CPF (75% inhibition). With radio-free